The utility of functional interaction and cluster analysis in CNS proteomics
暂无分享,去创建一个
Alan J. Gow | J. Mcculloch | R. Deighton | A. Gow | I. Whittle | James McCulloch | Ruth F. Deighton | Ian R. Whittle | Duncan M. Short | Richard J. McGregor | D. Short
[1] M. Eravci,et al. Results and reliability of protein quantification for two‐dimensional gel electrophoresis strongly depend on the type of protein sample and the method employed , 2008, Proteomics.
[2] J. Robben,et al. Treatment of missing values for multivariate statistical analysis of gel‐based proteomics data , 2008, Proteomics.
[3] J. Mcculloch,et al. Proteomic analysis of gliomas , 2007, British journal of neurosurgery.
[4] C. Vulpe,et al. Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins , 2008, Proteomics.
[5] S. Atlas,et al. Magnetic resonance image–guided proteomics of human glioblastoma multiforme , 2003, Journal of magnetic resonance imaging : JMRI.
[6] Vani Santosh,et al. Differential protein expression in human gliomas and molecular insights , 2005, Proteomics.
[7] R. Stupp,et al. The Role of Radio- and Chemotherapy in Glioblastoma , 2005, Oncology Research and Treatment.
[8] Proteome analysis of cortical neuronal cultures following cycloheximide, heat stress and MK801 preconditioning , 2005, Proteomics.
[9] O. Bogler,et al. Proteomics: the new frontier also for brain tumor research. , 2008, Current problems in cancer.
[10] F. Zanella,et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.
[11] Karl J. Friston,et al. Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[12] I. Whittle,et al. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? , 2008, British journal of neurosurgery.
[13] John D. Storey. A direct approach to false discovery rates , 2002 .
[14] Emilio Marengo,et al. Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study , 2008, Analytical and bioanalytical chemistry.
[15] D. Dominguez,et al. Proteomics: Clinical Applications , 2007, American Society for Clinical Laboratory Science.
[16] Bruno Zanotti,et al. Proteomic studies on low- and high-grade human brain astrocytomas. , 2005, Journal of proteome research.
[17] Rony Seger,et al. The MEK/ERK cascade: from signaling specificity to diverse functions. , 2007, Biochimica et biophysica acta.
[18] A. Vortmeyer,et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme , 2004, Oncogene.
[19] E. Krause,et al. The whereabouts of transmembrane proteins from rat brain synaptosomes during two‐dimensional gel electrophoresis , 2008, Proteomics.
[20] M. Oshimura,et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. , 2003, Biochemical and biophysical research communications.
[21] J. Mcculloch,et al. Effect of Apomorphine on the Relationship between Local Cerebral Glucose Utilization and Local Cerebral Blood Flow (with an Appendix on its Statistical Analysis) , 1982, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] John Sharkey,et al. Apoptosis induced by staurosporine alters chaperone and endoplasmic reticulum proteins: Identification by quantitative proteomics , 2007, Proteomics.
[23] A. Vortmeyer,et al. Proteins and Protein Pattern Differences between Glioma Cell Lines and Glioblastoma Multiforme , 2005, Clinical Cancer Research.
[24] Aaron S. Gajadhar,et al. PROTEOMICS: PRESENT AND FUTURE IMPLICATIONS IN NEURO‐ONCOLOGY , 2008, Neurosurgery.
[25] R. Ramponi,et al. Clinical applications , 2007, Lasers in Medical Science.
[26] M. Girolami,et al. Clinical proteomics: A need to define the field and to begin to set adequate standards , 2007, Proteomics. Clinical applications.
[27] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[28] D. Butterfield,et al. Proteomics in animal models of Alzheimer's and Parkinson's diseases , 2009, Ageing Research Reviews.
[29] J. Mcculloch,et al. The effect of diazepam upon local cerebral glucose use in the conscious rat , 1986, Neuroscience.
[30] Ulrich Mansmann,et al. Technical strategies to reduce the amount of “false significant” results in quantitative proteomics , 2008, Proteomics.